MemorialCare Heart & Vascular Institute has introduced the FDA-approved Symplicity Renal Denervation procedure, a minimally invasive therapy now available at Long Beach Medical Center, Orange Coast Medical Center, and Saddleback Medical Center. Resistant hypertension affects roughly 17 to 20 percent of Americans with high blood pressure, or about 10 million people, who continue to experience elevated blood pressure despite using multiple medications. Clinical evidence shows that the procedure can lower the risk of major cardiovascular events by 20 percent, reduce stroke risk by 27 percent, and decrease heart failure by 28 percent in patients with resistant hypertension.
Health Technology Insights: The Guthrie Clinic Announces New Chief Digital Officer
“This treatment provides a new option for patients who have not responded to conventional therapies,” said David Shavelle, M.D., FACC, FSCAI, chief of cardiology at MemorialCare. “It is a safe and effective approach that works alongside current care plans to help patients achieve better blood pressure control. We are proud to offer this innovative therapy to our communities and help patients regain confidence and peace of mind.”
High blood pressure impacts nearly half of all adults in the United States and is a leading contributor to heart disease, stroke, and kidney failure. While many patients manage their blood pressure with lifestyle changes and medications, a significant number experience resistant hypertension, defined as high blood pressure that persists despite taking three or more antihypertensive medications.
Certain groups are at higher risk, including older adults, Black individuals, and patients with chronic conditions such as diabetes, chronic kidney disease, and obesity. Black adults are nearly 50 percent more likely to develop resistant hypertension than white adults, which puts them at greater risk for stroke, heart failure, and other major cardiovascular events. Innovations such as renal denervation are particularly valuable for these populations.
The procedure targets overactive nerves surrounding the renal arteries that contribute to elevated blood pressure. By delivering precise radiofrequency energy, the therapy helps the body naturally regulate blood pressure. Medtronic clinical trials indicate that a 10-millimeter reduction in office systolic blood pressure can reduce major cardiovascular events by 20 percent, stroke by 27 percent, and heart failure by 28 percent in patients with resistant hypertension. According to the American Heart Association, patients with resistant hypertension face up to 56 percent higher cardiovascular mortality compared to those with controlled blood pressure, making this therapy an important option for patients whose condition remains uncontrolled despite medication and lifestyle management.
Health Technology Insights: Rocket Doctor AI Partners to Boost AI Clinical Support in Alberta
“Research shows that renal denervation can lower both systolic and diastolic blood pressure, support long-term stability, and reduce the need for multiple medications,” said Dr. Shavelle. “This minimally invasive approach complements existing treatment plans and provides a safe and effective option for patients who cannot tolerate certain blood pressure drugs.”
The Symplicity Spyral RDN system from Medtronic uses a thin, flexible catheter to deliver targeted energy to the nerves around the renal arteries. A small incision near the upper leg or groin allows the catheter to reach the arteries, where energy is applied to calm the nerves without damaging the vessel. The procedure typically takes about an hour, and most patients return home the same day or after a brief observation period, avoiding the need for surgery or permanent implants.
The rollout of renal denervation at MemorialCare demonstrates the health system’s commitment to advanced cardiovascular care. By expanding access to innovative therapies, MemorialCare aims to improve outcomes for patients with complex heart conditions and provide solutions for those who struggle to manage resistant hypertension with conventional treatments.
Health Technology Insights: Amphista Reveals AMX-883 Preclinical Data for AML Therapy
To participate in our interviews, please write to our HealthTech Media Room at info@intentamplify.com
